Novozymes A-S Aktie
| 49,74EUR | -0,13EUR | -0,26% |
WKN DE: A1JP9Y / ISIN: DK0060336014
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 6 527 | 6 781 | 6 756 | 10 582 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 2,29 | 2,59 | 2,65 | 2,70 | 0,00 |
Bilanz (in Mio. DKK) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 7 823 | 9 241 | 9 462 | 14 015 | 0 |
| Summe Anlagevermögen | 17 405 | 18 772 | 19 132 | 106 617 | 0 |
| Summe Aktiva | 25 228 | 28 013 | 28 594 | 120 632 | 122 112 |
Bilanz (in Mio. DKK) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 13 022 | 13 785 | 14 243 | 37 290 | 0 |
| Summe Eigenkapital | 12 206 | 14 228 | 14 351 | 83 342 | 81 078 |
| Summe Passiva | 25 228 | 28 013 | 28 594 | 120 632 | 0 |
Adresse
| Biologiens Vej 2, 2800 Lyngby | |
| Internet | http://www.novonesis.com |
Management
|
Anders Lund
Chief Operating Officer |
|
Cees de Jong
Chairman |
|
Claus Crone Fuglsang
Chief Scientific Officer |
|
Ester Baiget
President & Chief Executive Officer |
|
Frederikke Rose Spenner
Director |
|
Heine Dalsgaard
Non-Independent Director |
|
Henrik Joerck Nielsen
Executive VP-Strategy & Integration |
|
Jens Kolind
Senior Vice President |
|
Kasim Kutay
Non-Independent Director |
|
Kevin Lane
Independent Director |
|
Kim Stratton
Independent Director |
|
Lars Bo Koppler
Director |
|
Lise Kaae Lövbjerg
Independent Director |
|
Monila Kothari
Independent Director |
|
Morten Enggaard Rasmussen
Executive VP-People & Stakeholder Relations |
|
Morten Otto Alexander Sommer
Independent Director |
|
Preben Nielsen
Director |
|
Rainer Lehmann
Chief Financial Officer |
|
Robert Noddeskov Jensen
Director |
|
Tobias Cornelius Bjorklund
Head-Investor Relations |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.